About Sputnik Light

About Sputnik Light

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V – the world’s first registered vaccine against coronavirus.

The Sputnik Light vaccine, like Sputnik V, is based on a proven well-studied human adenovirus vector platform; these vectors cause the common cold and have peacefully coexisted with humanity for millenia.

Safety of Sputnik Light, as the first component of Sputnik V, was confirmed by real-world data from UAE, Bahrain, Argentina, Russia, Mexico, Serbia, San Marino, Philippines, Libya, Paraguay, Hungary, Azerbaijan and Belarus.

Sputnik Light, the first component of Sputnik V, is a safe and approved stand-alone one-shot vaccine
80%

proven efficacy against infection,
higher than that of most two-shot vaccines

The efficacy against hospitalization and severe disease is even higher

Sputnik Light is also a leading booster shot

  • for people previously infected with COVID-19
  • for revaccinations after Sputnik V or other vaccines

Sputnik Light as a stand-alone vaccine is highly effective against Delta and other mutations

efficacy against
infection by Delta

efficacy in the age
group below 60

higher than that of most two-shot vaccines

  • Efficacy against hospitalization and severe disease is even higher

Sputnik Light efficacy as a booster will be close to that of two shots of Sputnik V against Delta

effective against
infection

effective against
hospitalization

Sputnik Light has a long-lasting protection, which even increases over 4-6 months following the vaccination.

Many other vaccines showed dramatic decrease in efficacy against Delta variant to below 50% within the same time period.

Sputnik Light safety was confirmed by real-world data from multiple countries and by over 20 publications in the leading international scientific journals.

  • Sputnik Light is safe and effective in combination with other vaccines as confirmed by joint international clinical trials with the AstraZeneca, Sinopharm and Moderna vaccines
  • This vaccine coctail or mix & match approach has been poineered by Sputnik V.

Sputnik Light, the first component of Sputnik V, became a significant part of immunization programme in Argentina

40,000
35,000
30,000
25,000
20,000
15,000
10,000
5,000
Over 35 times reduction in new COVID-19 cases over the last 4 months
  • daily new cases
  • daily new cases (7 days average)
Jun, 2021
Jul, 2021
Aug, 2021
Sep, 2021
Oct, 2021

Source: JHU CSSE COVID-19 Data

Phase I/II of the Safety and Immunogenicity Study of the Sputnik Light vaccine has demonstrated that:

  • Sputnik Light can elicit the development of antigen specific IgG antibodies in 96.9% of individuals on the 28th day after vaccination;
  • The Sputnik Light vaccine elicits the development of virus neutralizing antibodies in 91.67% of individuals on the 28th day post immunization;
  • Cellular immune response against the S Protein of SARS-CoV-2 develops in 100% of volunteers on the 10th day;
  • The immunization of individuals with pre-existing immunity against SARS-CoV-2 with Sputnik Light can elicit the increase of the level of antigen specific IgG antibodies by more than 40x in 100% of subjects 10 days after immunization;
  • No serious adverse events were registered after vaccination with Sputnik Light.

Message has been successfully sent!

Thank you!
You have been subscribed